Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30486
Title: The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer.
Austin Authors: Cheung, Yee-Ming Melody ;Hughes, Melissa;Harrod, Julia;Files, Janet;Kirkner, Greg;Buckley, Lauren;Lin, Nancy U;Tolaney, Sara M;McDonnell, Marie E;Min, Le
Affiliation: Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA..
Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA 02215, USA..
Medicine (University of Melbourne)
Issue Date: 29-Jun-2022
Date: 2022
Publication information: The Journal of clinical endocrinology and metabolism 2022; online first: 29 June
Abstract: It is unclear whether diabetes and glycemic control affects the outcomes of breast cancer, especially amongst those with metastatic disease. This study aims to determine the impact of diabetes and hyperglycemia on cancer progression and mortality in individuals with metastatic breast cancer (MBC). Patients with a diagnosis of MBC between 2010-2021 were identified using the MBC database at two academic institutions. We evaluated the effects of diabetes and glycemic control on overall survival (OS) and time to next treatment (TTNT). We compared 244 patients with diabetes (median age 57.6 years) to 244 patients without diabetes (matched for age, sex, ethnicity and receptor subtype). OS at 5-years (diabetes: 54%, 95% CI; 47-62% vs. controls: 56%, 95% CI; 49-63%, p=0.65) and TTNT at 1-year (diabetes: 43%, CI; 36-50% vs. controls: 44%, CI; 36-51%, p=0.33) were similar between groups. A subgroup analysis comparing those with good and poor glycemic control amongst patients with specific receptor subtype profiles, showed no differences in OS at 5-years, or TTNT at 1-year. In an 8-year landmark subgroup analysis, there was worse OS amongst individuals with diabetes compared to controls, and OS was found to be better amongst those with good glycemic control compared to those with poor control. Diabetes was not associated with increased mortality in individuals with MBC at 5-years. However, diabetes and hyperglycemia were associated with worse OS amongst a cohort of longer-term survivors. These findings suggest that individualized diabetes and glycemic goals should be considered in patients with MBC.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30486
DOI: 10.1210/clinem/dgac375
ORCID: 0000-0002-9126-1948
0000-0003-3875-5698
Journal: The Journal of clinical endocrinology and metabolism
PubMed URL: 35766387
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35766387/
Type: Journal Article
Subjects: cancer outcomes
diabetes
hyperglycemia
metastatic breast cancer
overall survival
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on May 30, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.